Mentorship in research on opioid use disorder, HIV and marginalized populations

指导阿片类药物使用障碍、艾滋病毒和边缘化人群的研究

基本信息

批准号：
10619044
负责人：
Aaron D Fox
金额：
$ 18.48万
依托单位：
ALBERT EINSTEIN COLLEGE OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-08-15 至 2028-07-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10619044
关键词：
AIDS prevention Acquired Immunodeficiency Syndrome Advertisements Advisory Committees Area Award Baseline Surveys Behavior Black Populations Black race Buprenorphine COVID-19 Characteristics Client Clinic Clinical Clinical Investigator Clinical Research Clinical Treatment Clinical Trials Collaborations Complement County Data Dedications Diagnostic Reagent Kits Disease Outbreaks Dose Education Effectiveness Emergency Situation Enrollment Environment Equipment Exclusion Face Facebook Frequencies Fright Future Geographic Locations Geography Goals Grant Guidelines HIV HIV Infections HIV risk Harm Reduction Health Policy Helping to End Addiction Long-term Hepatitis C Transmission Hepatitis C virus Home Hospitalization Hospitals Hour Human immunodeficiency virus test Imprisonment Individual Informed Consent Injecting drug user Injections Internet Intervention Latinx Latinx population Law Enforcement Laws Leadership Link Longitudinal cohort study Measures Mediating Medical Medical center Medicine Mentors Mentorship Mid-Career Clinical Scientist Award (K24)Modeling Naloxone Needle-Exchange Programs Overdose Participant Persons Pharmaceutical Preparations Pharmacy facility Physicians Policies Population Prevalence Prevention Measures Prevention Research Primary Care Principal Investigator Privacy Procedures Public Health Puerto Rico Questionnaires Randomized, Controlled Trials Research Research Methodology Research Personnel Resources Risk Risk Assessment Risk Behaviors Rural Safety Sampling Scientist Secure Self Administration Services Source Sterility Surveys Syringes Talents Technology Test Result Testing Time Training Translating Translational Research Transportation Twitter Underserved Population United States United States National Institutes of Health Woman Youth addiction buprenorphine treatment career career development chronic pain chronic pain patient cohort college cost effectiveness efficacy testing eligible participant evidence base experience feasibility testing follow-up high risk housing instability injection drug use innovation marginalized population member mid-career faculty multidisciplinary novel opioid epidemic opioid use disorder overdose risk participant enrollment patient oriented research peer support prevention service primary outcome programs recruit satisfaction screening service uptake skills social social media social stigma sociodemographics uptake urban setting web platform web site

项目摘要

Mentorship in research on opioid use disorder, HIV and marginalized populations People who inject drugs (PWID) are at high risk for overdose and increasing HIV risk, yet they sub-optimally receive evidence-based opioid use disorder (OUD) treatment and HIV prevention measures. Engaging PWID and persons with OUD from marginalized groups requires innovative approaches. Aaron D. Fox, MD MS is an Addiction Medicine physician and Associate Professor of Medicine at Albert Einstein College of Medicine- Montefiore Medical Center. He is an experienced research mentor, the director of the Bronx Transitions Clinic, which provides a medical home to formerly incarcerated individuals, and the principal investigator of two clinical trials of innovative buprenorphine treatment interventions (see below). Einstein-Montefiore’s Institute for Clinical and Translational Research, and the Einstein-Rockefeller-CUNY Center for AIDS Research, provide an outstanding environment for supporting early-stage investigators and trainees. As part of the NIH HEAL initiative, Einstein-Montefiore was recently awarded one of four IMPOWR grants to develop a research center on chronic pain and OUD. In this K24 mid-career mentorship award, Dr. Fox proposes to capitalize upon these resources in mentoring six talented early-stage investigators in research on OUD, HIV, and marginalized populations. Dr. Fox would also gain skills in mentoring, new research methods, and drug policy leadership with the following career development objectives: 1) To provide outstanding mentorship to diverse early-stage investigators who will develop independent research careers in OUD treatment and HIV prevention; 2) To gain skills in internet-mediated HIV prevention research; and 3) To translate evidence into clinical guidelines and policy regarding access to addiction treatment and HIV prevention services. To meet these objectives, Dr. Fox will convene an advisory team with expertise in mentoring, internet-mediated research, and drug policy, while participating in training specific to research mentoring and health policy leadership. Dr. Fox’s current studies provide a unique environment where early-stage investigators can participate in patient-oriented research in primary care, hospitals, syringe services programs, and a post-incarceration “transitions clinic.” Dr. Fox leads two large randomized controlled trials: buprenorphine microdose inductions for hospitalized patients with chronic pain (RM1DA055437), and the effectiveness, safety, and cost-effectiveness of buprenorphine treatment initiation at syringe services programs (R01DA044878). This application also proposes new internet- mediated HIV prevention research in collaboration with NEXT Distro, the first formal internet-based mail delivery syringe services program in the United States. These studies will serve as a platform for trainees to develop careers in patient-oriented research that is highly relevant for drug policy and clinical guidelines. Completion of the proposed K24 award would advance research in OUD treatment and HIV prevention, while also expanding and diversifying the research workforce dedicated to OUD, HIV, and marginalized populations.

关于阿片类药物使用障碍，艾滋病毒和边缘化人群的研究指导注射毒品（PWID）的人有过量的高风险和增加艾滋病毒的风险，但他们是优选的接受基于证据的阿片类药物使用障碍（OUD）治疗和HIV预防措施。引人入胜的pwid 来自边缘化团体的OUD的人需要创新的方法。亚伦·福克斯（Aaron D. Fox），医学博士是阿尔伯特·爱因斯坦医学院的成瘾医学物理和医学副教授 - 蒙特菲奥尔医疗中心。他是经验丰富的研究心态，布朗克斯过渡诊所的主任，它为以前继承的个人提供了医疗住所，以及两个的主要调查员创新的丁丙诺啡治疗干预措施的临床试验（见下文）。爱因斯坦 - 蒙特菲奥雷的研究所临床和转化研究，以及爱因斯坦 - 罗科菲勒 - 纽约市艾滋病研究中心，提供了一个支持早期调查人员和学员的杰出环境。作为NIH治愈的一部分 Einstein-Montefiore倡议最近被授予开发研究中心的四项Impowr赠款之一关于慢性疼痛和oud。在这个K24中期心态奖中，福克斯博士提议将其利用在六个有才华的早期研究人员的精神上的OUD，HIV研究和边缘化的资源人群。福克斯博士还将获得心理，新研究方法和药物政策领导力的技能具有以下职业发展目标：1）为潜水员早期提供出色的心态将在OUD治疗和预防HIV方面发展独立研究职业的研究人员； 2）获得互联网介导的HIV预防研究技能； 3）将证据转化为临床准则和有关获得成瘾治疗和艾滋病毒预防服务的政策。为了达到这些目标，福克斯博士将方便一个在心理，互联网介导的研究和药物政策方面具有专业知识的咨询团队，而参加针对研究心理和健康政策领导的培训。福克斯博士的目前研究提供独特的环境，早期研究人员可以参与以患者为导向的研究初级保健，医院，注射器服务计划和监禁后“过渡诊所”。福克斯博士领导两项大型随机对照试验：用于住院的患者的丁丙诺啡诱导慢性疼痛（RM1DA055437）以及丁丙诺啡的有效性，安全性和成本效益注射器服务计划的治疗计划（R01DA044878）。该应用程序还建议新的互联网 - 与Next Distro合作的介导的HIV预防研究，这是第一个基于Internet的正式邮件美国的交付注射器服务计划。这些研究将成为培训的平台与药物政策和临床指南高度相关的患者研究中发展职业。拟议的K24奖的完成将提高Oud治疗和预防HIV的研究，而还扩大和多元化的研究人员专门针对OUD，HIV和边缘化人群。